These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 17719520)

  • 1. Rasagiline as a therapy for Parkinson's disease (PD).
    Hermanowicz N
    Am J Geriatr Pharmacother; 2007 Jun; 5(2):174-5; author reply 175-6. PubMed ID: 17719520
    [No Abstract]   [Full Text] [Related]  

  • 2. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rasagiline in Parkinson's disease.
    Chahine LM; Stern MB
    Int Rev Neurobiol; 2011; 100():151-68. PubMed ID: 21971007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New drug treatment for Parkinson's disease.
    FDA Consum; 2006; 40(4):7. PubMed ID: 17245831
    [No Abstract]   [Full Text] [Related]  

  • 5. Rasagiline. Parkinson's disease: a simple me-too.
    Prescrire Int; 2006 Dec; 15(86):220. PubMed ID: 17167927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rasagiline. Teva Pharmaceutical.
    Kupsch A
    Curr Opin Investig Drugs; 2002 May; 3(5):794-7. PubMed ID: 12090555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rasagiline -- is there a place for this drug in managing Parkinson's disease?
    Sharma JC
    Int J Clin Pract; 2006 Feb; 60(2):132-3. PubMed ID: 16451281
    [No Abstract]   [Full Text] [Related]  

  • 11. Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease.
    Stocchi F
    Int J Clin Pract; 2006 Feb; 60(2):215-21. PubMed ID: 16451296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rasagiline in Parkinson's disease].
    Linazasoro G
    Neurologia; 2008 May; 23(4):238-45. PubMed ID: 18307054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
    Weinreb O; Amit T; Bar-Am O; Youdim MB
    Prog Neurobiol; 2010 Nov; 92(3):330-44. PubMed ID: 20600573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Rasagiline: effectiveness and protection in Parkinson's disease].
    Pagonabarraga J; Kulisevsky J
    Rev Neurol; 2010 Nov; 51(9):535-41. PubMed ID: 20979033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
    Fernandez HH; Chen JJ
    Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline.
    Degli Esposti L; Piccinni C; Sangiorgi D; Nobili F; Buda S
    Neurol Sci; 2016 Feb; 37(2):227-34. PubMed ID: 26474874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rasagiline in motor fluctuations].
    Miletzki A
    Fortschr Neurol Psychiatr; 2005 Sep; 73(9):488. PubMed ID: 16217881
    [No Abstract]   [Full Text] [Related]  

  • 18. MAO-B inhibitor know-how: back to the pharm.
    Lewitt PA
    Neurology; 2009 Apr; 72(15):1352-7. PubMed ID: 19365057
    [No Abstract]   [Full Text] [Related]  

  • 19. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.
    Mandel S; Weinreb O; Amit T; Youdim MB
    Brain Res Brain Res Rev; 2005 Apr; 48(2):379-87. PubMed ID: 15850677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selegiline in Parkinson's disease.
    Calne DB
    BMJ; 1995 Dec; 311(7020):1583-4. PubMed ID: 8555790
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.